233 related articles for article (PubMed ID: 28131278)
21. Minimizing off-Target Mutagenesis Risks Caused by Programmable Nucleases.
Ishida K; Gee P; Hotta A
Int J Mol Sci; 2015 Oct; 16(10):24751-71. PubMed ID: 26501275
[TBL] [Abstract][Full Text] [Related]
22. [Applications of ZFN, TALEN and CRISPR/Cas9 techniques in disease modeling and gene therapy].
Zhao G; Pu J; Tang B
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2016 Dec; 33(6):857-862. PubMed ID: 27984622
[TBL] [Abstract][Full Text] [Related]
23. Construction and Evaluation of Zinc Finger Nucleases.
Ochiai H; Yamamoto T
Methods Mol Biol; 2023; 2637():1-25. PubMed ID: 36773134
[TBL] [Abstract][Full Text] [Related]
24. Controlled delivery of β-globin-targeting TALENs and CRISPR/Cas9 into mammalian cells for genome editing using microinjection.
Cottle RN; Lee CM; Archer D; Bao G
Sci Rep; 2015 Nov; 5():16031. PubMed ID: 26558999
[TBL] [Abstract][Full Text] [Related]
25. Detection of CRISPR/Cas9-Mediated Fetal Hemoglobin Reactivation in Erythroblasts Derived from Cord Blood-Hematopoietic Stem Cells.
Maroofi N; Maleki MSM; Tahmasebi M; Khorshid HRK; Modaberi Y; Najafipour R; Banan M
Mol Biotechnol; 2024 Apr; ():. PubMed ID: 38649638
[TBL] [Abstract][Full Text] [Related]
26. Genome Editing of Rat.
Kaneko T
Methods Mol Biol; 2017; 1630():101-108. PubMed ID: 28643253
[TBL] [Abstract][Full Text] [Related]
27. Recent Advances in the Production of Genome-Edited Rats.
Sato M; Nakamura S; Inada E; Takabayashi S
Int J Mol Sci; 2022 Feb; 23(5):. PubMed ID: 35269691
[TBL] [Abstract][Full Text] [Related]
28. PLGA-Nanoparticles for Intracellular Delivery of the CRISPR-Complex to Elevate Fetal Globin Expression in Erythroid Cells.
Cruz LJ; van Dijk T; Vepris O; Li TMWY; Schomann T; Baldazzi F; Kurita R; Nakamura Y; Grosveld F; Philipsen S; Eich C
Biomaterials; 2021 Jan; 268():120580. PubMed ID: 33321292
[TBL] [Abstract][Full Text] [Related]
29. Genome editing: the road of CRISPR/Cas9 from bench to clinic.
Eid A; Mahfouz MM
Exp Mol Med; 2016 Oct; 48(10):e265. PubMed ID: 27741224
[TBL] [Abstract][Full Text] [Related]
30. Genome editing with engineered nucleases in plants.
Osakabe Y; Osakabe K
Plant Cell Physiol; 2015 Mar; 56(3):389-400. PubMed ID: 25416289
[TBL] [Abstract][Full Text] [Related]
31. Genome Editing in Sugarcane: Challenges Ahead.
Mohan C
Front Plant Sci; 2016; 7():1542. PubMed ID: 27790238
[TBL] [Abstract][Full Text] [Related]
32. Advance of Clustered Regularly Interspaced Short Palindromic Repeats-Cas9 System and Its Application in Crop Improvement.
Rao Y; Yang X; Pan C; Wang C; Wang K
Front Plant Sci; 2022; 13():839001. PubMed ID: 35645999
[TBL] [Abstract][Full Text] [Related]
33. The CRISPR/Cas9 system for plant genome editing and beyond.
Bortesi L; Fischer R
Biotechnol Adv; 2015; 33(1):41-52. PubMed ID: 25536441
[TBL] [Abstract][Full Text] [Related]
34. Gene correction of HBB mutations in CD34
Antony JS; Latifi N; Haque AKMA; Lamsfus-Calle A; Daniel-Moreno A; Graeter S; Baskaran P; Weinmann P; Mezger M; Handgretinger R; Kormann MSD
Mol Cell Pediatr; 2018 Nov; 5(1):9. PubMed ID: 30430274
[TBL] [Abstract][Full Text] [Related]
35. Therapeutic Genome Editing and In Vivo Delivery.
Ramirez-Phillips AC; Liu D
AAPS J; 2021 Jun; 23(4):80. PubMed ID: 34080099
[TBL] [Abstract][Full Text] [Related]
36. Genome editing using CRISPR-Cas9 to create the HPFH genotype in HSPCs: An approach for treating sickle cell disease and β-thalassemia.
Ye L; Wang J; Tan Y; Beyer AI; Xie F; Muench MO; Kan YW
Proc Natl Acad Sci U S A; 2016 Sep; 113(38):10661-5. PubMed ID: 27601644
[TBL] [Abstract][Full Text] [Related]
37. Genetic Manipulation Strategies for β-Thalassemia: A Review.
Zakaria NA; Bahar R; Abdullah WZ; Mohamed Yusoff AA; Shamsuddin S; Abdul Wahab R; Johan MF
Front Pediatr; 2022; 10():901605. PubMed ID: 35783328
[TBL] [Abstract][Full Text] [Related]
38. [CRISPR/Cas9-based genome editing systems and the analysis of targeted genome mutations in plants].
Ma XL; Liu YG
Yi Chuan; 2016 Feb; 38(2):118-25. PubMed ID: 26907775
[TBL] [Abstract][Full Text] [Related]
39. Genome editing of oncogenes with ZFNs and TALENs: caveats in nuclease design.
Shankar S; Sreekumar A; Prasad D; Das AV; Pillai MR
Cancer Cell Int; 2018; 18():169. PubMed ID: 30386178
[TBL] [Abstract][Full Text] [Related]
40. Targeted Mutagenesis in Rice Using TALENs and the CRISPR/Cas9 System.
Endo M; Nishizawa-Yokoi A; Toki S
Methods Mol Biol; 2016; 1469():123-35. PubMed ID: 27557690
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
